ARCTIC trial shows excellent 10-year outcomes with treat-to-target strategy in early rheumatoid arthritis
A new study from the ARCTIC trial demonstrates that patients with early rheumatoid arthritis managed with a treat-to-target strategy achieved favorable long-term outcomes over 10 years. Patients who achieved sustained remission at two years showed higher remission rates and better physical function throughout the decade-long follow-up period.
